PRKCB and cancer: Since most detected mutations are heterozygous in cancer cells, the attempt to restore the endogenous PKCβ mutated gene (A509T) by using the CRISPR/Cas9 approach has led to an increase in terms of both expression levels and the basal activity of PKCβ [25].